| Study title |
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment (AHFIRM) |
| Disease or condition |
Alcoholic Hepatitis |
| Study type |
Intervention (Clinical Trial) |
| Intervention/treatment |
DUR-928 30 mg, DUR-928 90 mg, or Placebo+Standard of Care (SOC) |
| Phase |
2b |
| Study site |
Carolinas Medical Center, Center for Liver Disease & Transplant (Atrium Health) |
| Study location |
Charlotte, NC |
| Principal investigator name and email |
Mark Russo, MD |
| Study coordinator name and email |
Marybeth Schwallie@atriumhealth.org |
| Phone contact |
704-355-7608 |
| Clinicaltrials.gov link |
https://clinicaltrials.gov/ct2/show/NCT04563026 |
